Business
Cellectar raises USD 140m in oversubscribed financing for oncology programs
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company based in Florham Park, New Jersey focused on targeted oncology...
Elaris acquires Matrivax C. difficile vaccine assets via equity stake and royalties deal
Vienna-based Elaris FlexCo has entered into an asset purchase agreement with US-based Matrivax Research & Development Corporation to acquire intellectual...
Apertura Gene Therapy and TSC Alliance collaborate on AAV gene therapy for tuberous sclerosis complex
Apertura Gene Therapy has entered a collaboration agreement with the TSC Alliance, a Silver Spring, Maryland-based patient advocacy organization founded in...
Madrigal picks up Arrowhead's ARO-PNPLA3 MASH program in potential USD 1b deal
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has granted an exclusive worldwide license for ARO-PNPLA3, its Phase I-stage RNAi therapeutic targeting the PNPLA3...
Merck revises TERN-701 efficacy down, navigates mixed Welireg results, accelerates enlicitide timeline
Merck held its Q1 2026 earnings conference call on April 30, 2026, during which the company's pipeline narrative was dominated by three converging signals:...
GSK's Q1'26 Earnings Call: bepirovirsen in HBV, ADC pipeline in focus
GSK's Q1 2026 earnings conference call, held April 29, 2026, centered on three converging pipeline signals: positive Phase III data for bepirovirsen in...
Amgen's Q1'26 Earnings Call: Executives discuss MariTide Phase III program, Tavneos regulatory challenge
Amgen's AMGN Q1 2026 earnings conference call, held April 30, 2026, was dominated by three pipeline signals: an expanding Phase III program for MariTide...
Hemab Therapeutics raises USD 346.7m via Nasdaq listing to fund rare blood disorder therapies
Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) announced the closing of its initial public offering on May 4, 2026, raising approximately USD 346.7...
Cabaletta Bio raises USD 150m via share offering
Cabaletta Bio (Nasdaq: CABA), a Philadelphia-based clinical-stage cell therapy company, announced the pricing of an underwritten public offering to raise...
Cue Biopharma raises USD 30m in private placement PIPE financing
Boston-based Cue Biopharma, Inc. (Nasdaq: CUE) announced a USD 30 million PIPE financing on April 30, 2026, with proceeds directed toward advancing its...
Climb Bio raises USD 110m in private placement for immune-disease pipeline
Wellesley Hills, Massachusetts-based Climb Bio, Inc. (Nasdaq: CLYM) announced a USD 110.0 million private placement to fund continued clinical development...
Rein Therapeutics raises USD 50m in public share offering
US-based Rein Therapeutics (Nasdaq: RNTX) announced an underwritten public offering of common stock priced at USD 50 million, with proceeds designated to...
Aura Biosciences raises USD 260.3m in public offering of common stock
Aura Biosciences (Nasdaq: AURA) announced the pricing of an underwritten public offering to fund registration-enabling activities for its lead asset,...
Oruka Therapeutics raises USD 700.4m in underwritten public offering
Menlo Park, California-based Oruka Therapeutics, Inc. (Nasdaq: ORKA) announced the pricing of an upsized underwritten public offering on April 28, 2026,...
Windward Bio closes USD 165m financing for long-acting immunology therapies
Basel-based Windward Bio has closed a USD 165 million crossover financing round to advance its pipeline of long-acting antibody therapies targeting serious...
The AllSci Brief
Systematic R&D and deal news. Daily.